Comparison of MODIFIED progression-free survival (Modified-PFS) in high-dose rituximab (500mg/m²) plus CHOP versus standard-dose rituximab plus CHOP in previously untreated (TN) stage III-IV male DLBCL patients
age <75y, male patients
According to the 2017 Revised WHO Classification criteria for lymphoma, the subject was diagnosed with DLBCL
According to Ann Arbor staging, patients were classified as stage III-IV patients
No previous anti-tumor systemic therapy or local radiation therapy for DLBCL
Subjects assessed by the investigator to be intolerant to the R-CHOP regimen and/or any drug therapy;
Any previous anti-lymphoma systemic therapy or local radiation therapy
Consider patients with lymphoma involving the central nervous system (CNS) or diagnosed with primary CNS lymphoma (PCNSL); The diagnosis was primary mediastinal large B-cell lymphoma (PMBL)
Previously received organ transplantation or hematopoietic stem cell transplantation
Xia Yi
Lead sponsor
Sun Yat-Sen University Cancer Center
Sponsor institution